Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging such as Type 2 Diabetes, announced that it will
be presenting at the American Chemical Society annual meeting in New
Orleans on Monday, April 7 at 7:00 pm EDT.
Jean Bemis, Sirtris Associate Director of Chemistry, will present an
abstract on the identification of novel small molecule activators of
SIRT1, the founding member of the sirtuin family of enzymes associated
with diseases of aging. Using high throughput mass spectrometry, Sirtris
has identified new chemical entity (NCE) activators of SIRT1 that are
chemically distinct from, and up to 1000 times more potent in in-vitro
studies than resveratrol, the compound shown to reduce glucose and
improve insulin sensitivity in preclinical studies.
Sirtris’ NCEs have been shown to lower glucose
and improve insulin sensitivity in predictive pre-clinical models of
Type 2 Diabetes. SIRT1 activators have the potential to be a frontline
therapy for Type 2 Diabetes.
Sirtris plans to have one of its NCEs in a Phase 1 human clinical safety
trial in the first half of 2008.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that the
Company believes control the aging process. Sirtris Pharmaceuticals is
engaged in human clinical trials for Type 2 Diabetes, and is planning
similar trials in cancer, another age-related disease. Sirtris is also
engaged in a human clinical trial for MELAS, a mitochondrial disorder.
The company's headquarters are in Cambridge, Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the potential therapeutic
effects of SIRT1 activators including NCEs for diseases of aging, such
as Type 2 Diabetes; the success of SIRT1 activators as therapies for
diseases, such as Type 2 Diabetes; the progress and results of
preclinical and clinical studies of SIRT1 activators, such as SRT501 and
Sirtris’ NCEs; and the potential of sirtuin
modulators to receive regulatory approval. These forward-looking
statements about future expectations, plans and prospects of Sirtris
Pharmaceuticals involve significant risks, uncertainties and
assumptions, including risks related to the lack of results that would
provide a basis for predicting whether any of the Company's product
candidates will be safe or effective, or receive regulatory approval,
the possibility that results of pre-clinical studies are not necessarily
predictive of clinical trial results, the Company's potential inability
to initiate and complete pre-clinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential inability of
the Company to gain market acceptance of the Company's product
candidates, and those other risks factors that can be found in the
Company's filings with the Securities and Exchange Commission. Actual
results may differ materially from those Sirtris Pharmaceuticals
contemplated by these forward-looking statements. Sirtris
Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or events or
circumstances that occur after the date of this release.